Kolon Corporation (002020) Q3 2024 earnings summary

Executive summary

• Consolidated sales for 2024 Q3 reached 4.49 trillion KRW, up 4.7% year-over-year, with net income surging 283.8% to 191.1 billion KRW, while operating profit dropped 79.8% to 25.2 billion KRW.

• The group completed several major M&A and restructuring activities, including the acquisition of Kolon TissueGene and Kolon Space Works, and the absorption of Kolon Glotech's automotive materials business.

• The company maintains a diversified portfolio across holding, construction, mobility, IT, pharma, and bio segments, with ongoing investments in R&D and new business lines.

Financial highlights

• Q3 2024 consolidated revenue: 4.49 trillion KRW (+4.7% YoY); operating profit: 25.2 billion KRW (-79.8% YoY); net income: 191.1 billion KRW (+283.8% YoY).

• Total assets: 6.39 trillion KRW; total liabilities: 4.76 trillion KRW; equity: 1.63 trillion KRW.

• Debt-to-equity ratio: 291.9% (down from 299.2% at prior year-end).

• Dividend: 550 KRW per common share, 600 KRW per preferred share.

Outlook and guidance

• The group expects continued growth in construction and mobility, with new investments in bio and IT segments.

• Ongoing cost controls and portfolio optimization are planned to improve operating margins.

• R&D and pipeline expansion in pharmaceuticals and bio are expected to drive future value.